Barr, Lilly Dismiss Prozac Patent Suit

Law360, New York (June 4, 2007, 12:00 AM EDT) -- Barr Pharmaceuticals Inc. and Eli Lilly & Co. have voluntarily dismissed all claims against each other in a patent infringement suit over the blockbuster antidepressant Prozac.

Judge Larry J. McKinney of the U.S. District Court for the Southern District of Indiana approved the dismissal on Monday. It was a victory for Barr, which is looking to market a generic version of Eli Lilly's Prozac Weekly 90 mg capsules, the active ingredient of which is fluoxetine hydrochloride.

“Barr...believes it is the first to file an Abbreviated New...
To view the full article, register now.